Nicox acquires Aciex in stock deal: $65M up front, $55M contingent payments
By Cormac Sheridan
Wednesday, July 2, 2014
Nicox SA is paying $65 million up front and could pay up to $55 million more in a cash-free, stock-based acquisition of Aciex Therapeutics Inc. that gives it a near-term shot at a product approval.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.